Concomitant proton pump inhibitors and capecitabine-based chemoradiotherapy in rectal cancer: an ancillary study from the PRODIGE 23 trial

Background: Approximately one in five cancer patients use proton pump inhibitors (PPIs). In this work, we studied the effect of PPI co-medication during neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC) based on the phase III PRODIGE 23 trial. Materials and methods: We g...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	M. Bridoux, E. Aymes, T. Conroy, S. Gourgou, A. Carnot, C. Borg, M.-C. Le Deley, A. Turpin
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-03-01
Schriftenreihe:	ESMO Gastrointestinal Oncology
Schlagworte:	capecitabine-based chemoradiotherapy neoadjuvant chemoradiotherapy proton pump inhibitors overall survival recurrence-free survival
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2949819824000803
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!